Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$818.93 USD

818.93
5,263,033

-10.81 (-1.30%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $816.25 -2.68 (-0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Kinjel Shah headshot

5 Large Drug Stocks to Watch From a Thriving Industry

Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), AstraZeneca (AZN), Pfizer (PFE), Sanofi (SNY) and Bayer (BAYRY) are worth retaining in one's portfolio.

Eli Lilly (LLY) Rises But Trails Market: What Investors Should Know

Eli Lilly (LLY) concluded the recent trading session at $887.16, signifying a +0.18% move from its prior day's close.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More

FDA approves Sanofi's Dupixent for COPD. Eli Lilly is set to invest $4.5 billion to build a new manufacturing and research site in Indiana.

AbbVie Cuts 2024 Earnings Guidance to Include Acquisition Costs

ABBV lowers adjusted earnings guidance for 2024 from $10.71-$10.91 per share to $10.67-$10.87 to account for acquisition costs.

Mark Vickery headshot

Top Research Reports for Exxon Mobil, Mastercard and Procter & Gamble

Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), Mastercard Incorporated (MA) and The Procter & Gamble Company (PG), as well a micro-cap stock Vaso Corporation (VASO).

Eli Lilly to Invest $4.5B for New Manufacturing & Research Plant

Lilly is investing $4.5 billion to build a new site for improving manufacturing and drug development.

Are Medical Stocks Lagging Eli Lilly (LLY) This Year?

Here is how Eli Lilly (LLY) and BioLife Solutions, Inc. (BLFS) have performed compared to their sector so far this year.

Here's Why You Should Consider Buying Jazz Pharmaceuticals' Stock

Here, we discuss some reasons why buying JAZZ stock now may turn out to be a prudent move.

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

Sector ETF report for IYH

Kinjel Shah headshot

Should You Buy AbbVie Stock After Recent Parkinson's Study Success?

Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.

Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors

RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.

Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD

Sanofi and Regeneron's Dupixent becomes the first biologic treatment approved for COPD in the United States.

Bayer Reports Positive Safety Data on Parkinson's Disease Drug

BAYRY's experimental Parkinson's disease drug continues to show a favorable safety profile in all 12 participants in the trial's high and low-dose cohorts at 24 months.

Is Trending Stock Eli Lilly and Company (LLY) a Buy Now?

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Should Invesco Large Cap Growth ETF (PWB) Be on Your Investing Radar?

Style Box ETF report for PWB

Tracey Ryniec headshot

Stocks to Buy and Hold for 5 Years

What if you fell asleep and woke up 5 years later? Would you feel confident in your stock portfolio?

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's 3rd Talc-Related Bankruptcy Filing & More

JNJ files for voluntary bankruptcy for the third time. Pfizer withdraws sickle-cell drug drug Oxbryta from worldwide markets.

Bayer Submits Application for Label Expansion of Prostate Cancer Drug

BAYRY moves ahead with the submission of an application seeking approval of darolutamide in combination with androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

Eli Lilly (LLY) Stock Declines While Market Improves: Some Information for Investors

Eli Lilly (LLY) closed the most recent trading day at $909.32, moving -1.65% from the previous trading session.

Kinjel Shah headshot

Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health

Pfizer, Eli Lilly, AstraZeneca, Bayer and Sanofi can prove to be great additions to your portfolio.

Wall Street Analysts Think Lilly (LLY) Is a Good Investment: Is It?

The average brokerage recommendation (ABR) for Lilly (LLY) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Should SPDR MSCI USA StrategicFactors ETF (QUS) Be on Your Investing Radar?

Style Box ETF report for QUS

Should You Invest in the Vanguard Health Care ETF (VHT)?

Sector ETF report for VHT

Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan

Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in July 2024.